BeOne Medicines AG Revenue

In the year 2025, BeOne Medicines AG had annual revenue of $5.34B USD with 40.23% growth. BeOne Medicines AG had revenue of $1.50B in the quarter ending December 31, 2025, with 32.84% growth.

Revenue

$5.34B

Revenue Growth

+40.23%

P/S Ratio

6.11

Revenue / Employee

$485.73K

Employees

11,000

Market Cap

254.03B HKD

Revenue Chart

* This company reports financials in USD.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	5.34B	1.53B	40.23%
Dec 31, 2024	3.81B	1.35B	54.96%
Dec 31, 2023	2.46B	1.04B	73.65%
Dec 31, 2022	1.42B	239.64M	20.37%
Dec 31, 2021	1.18B	867.41M	280.83%
Dec 31, 2020	308.87M	-119.34M	-27.87%
Dec 31, 2019	428.21M	229.99M	116.03%
Dec 31, 2018	198.22M	-40.17M	-16.85%
Dec 31, 2017	238.39M	237.32M	22,179.16%
Dec 31, 2016	1.07M	-7.75M	-87.86%
Dec 31, 2015	8.82M	-4.22M	-32.37%
Dec 31, 2014	13.04M	1.89M	16.93%
Dec 31, 2013	11.15M	-	-

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Sino Biopharmaceutical	33.49B
WuXi Biologics	21.98B
Innovent Biologics	12.52B
3SBio	9.94B
Shanghai Henlius Biotech	6.35B
RemeGen	3.62B
Shanghai Junshi Biosciences	2.78B
Akeso	2.75B

Revenue Rankings

BeOne Medicines AG News

9 days ago - BeiGene (ONC) Q4 Earnings Preview: Revenue Set for Growth - GuruFocus
11 months ago - U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene - Business Wire
1 year ago - BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer - Business Wire

More News